Prospects for an AIDS vaccine: Three big questions, no easy answers

Lancet Infectious Diseases

Volumn 4, Issue 7, 2004, Pages 397-413

  Garber, David A ^a   Silvestri, Guido ^a   Feinberg, Mark B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD8 ANTIGEN; CHICKENPOX VACCINE; GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY ISOLATION; ANTIBODY RESPONSE; ANTIBODY TITER; CHICKENPOX; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSURVEILLANCE; MEMORY CELL; PRIORITY JOURNAL; REVIEW; TH1 CELL; VIRUS ENVELOPE; VIRUS LOAD; VIRUS PARTICLE; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CLINICAL TRIALS; HIV INFECTIONS; HUMANS; WORLD HEALTH;

EID: 3042662105     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(04)01056-4     Document Type: Review

References (173)

1. UNAIDS. AIDS epidemic update December 2003. Geneva, Switzerland: UNAIDS, 2003.
2. Cohen J. Public health. AIDS vaccine trial produces disappointment and confusion. Science. 299:2003;1290-1291
3. Follmann D, Gilbert P, Self S, et al. An independent analysis of the effect of race in VAX004. 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, CA.
4. Pitisutithum P. Efficacy of AIDSVAX B/E vaccines in injecting drug use. 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, CA.
5. Anon. VaxGen announces initial results of its phase III AIDS vaccine trial (press release); Feb 24, 2003. http://www.vaxgen.com/pressroom/index.html (accessed June 8, 2004).
6. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 280:1998;1884-1888
7. Kwong PD, Doyle ML, Casper DJ, et al. HIV-1 evades antibody-mediated neutralisation through conformational masking of receptor-binding sites. Nature. 420:2002;678-682
8. Check E. AIDS vaccines: back to 'plan A'. Nature. 423:2003;912-914
9. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol. 5:2004;233-236
10. Saphire EO, Parren PW, Pantophlet R, et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science. 293:2001;1155-1159
11. Calarese DA, Scanlan CN, Zwick MB, et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science. 300:2003;2065-2071
12. Choe H, Li W, Wright PL, et al. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell. 114:2003;161-170
13. McMichael A, Hanke T. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat Rev Immunol. 2:2002;283-291
14. Robinson HL. New hope for an AIDS vaccine. Nat Rev Immunol. 2:2002;239-250
15. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 122:1995;573-579
16. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 342:2000;921-929
17. Shiver J. Development of an HIV-1 vaccine based on replication-defective adenovirus. Keystone Symposium - HIV Vaccine Development: Progress and Prospects; 2004; Whistler, British Columbia, Canada.
18. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med. 55:2004;355-372
19. Feinberg MB. The interface between pathogenesis and treatment of HIV infection. Emini EA. The human immunodeficiency virus: biology, immunology, and therapy. 2002;384-440 Princeton University Press, Princeton
20. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 271:1996;324-328
21. Desrosiers RC. Prospects for an AIDS vaccine. Nat Med. 10:2004;221-223
22. Wyatt R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 393:1998;705-711
23. Johnson WE, Desrosiers RC. Viral persistance: HIV's strategies of immune system evasion. Annu Rev Med. 53:2002;499-518
24. Wei X, Decker JM, Wang S, et al. Antibody neutralisation and escape by HIV-1. Nature. 422:2003;307-312
25. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA. 100:2003;4144-4149
26. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al. Envelope-constrained neutralisation-sensitive HIV-1 after heterosexual transmission. Science. 303:2004;2019-2022
27. Cohen J. Virology. HIV may shed some protection as it jumps to new hosts. Science. 303:2004;1956
28. Farzan M, Mirzabekov T, Kolchinsky P, et al. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell. 96:1999;667-676
29. Lin G, Hoxie JA. CCR5 mimicry by sulfated human anti-HIV-1 antibodies. Cell. 114:2003;147-148
30. Huang CC, Venturi M, Majeed S, et al. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci USA. 101:2004;2706-2711
31. Igarashi T, Brown C, Azadegan A, et al. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat Med. 5:1999;211-216
32. Shibata R, Igarashi T, Haigwood N, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med. 5:1999;204-210
33. Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralisation in vitro. J Virol. 75:2001;8340-8347
34. Moore JP, Burton DR. HIV-1 neutralizing antibodies: how full is the bottle? Nat Med. 5:1999;142-144
35. Veazey RS, Shattock RJ, Pope M, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med. 9:2003;343-346
36. Binley JM, Sanders RW, Clas B, et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol. 74:2000;627-643
37. Korber B, Gaschen B, Yusim K, et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull. 58:2001;19-42
38. Connor RI, Korber BT, Graham BS, et al. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol. 72:1998;1552-1576
39. Locher CP, Grant RM, Collisson EA, et al. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination. AIDS Res Hum Retroviruses. 15:1999;1685-1689
40. Yang OO, Kalams SA, Rosenzweig M, et al. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. J Virol. 70:1996;5799-5806
41. Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA. 91:1994;3764-3768
42. Guidotti LG, Ishikawa T, Hobbs MV, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 4:1996;25-36
43. Wagner L, Yang OO, Garcia-Zepeda EA, et al. Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature. 391:1998;908-911
44. Garzino-Demo A, DeVico AL, Cocchi F, Gallo RC. Beta-chemokines and protection from HIV type 1 disease. AIDS Res Hum Retroviruses. 14:(suppl 2):1998;177-184
45. Rubbert A, Weissman D, Combadiere C, et al. Multifactorial nature of noncytolytic CD8+ T cell-mediated suppression of HIV replication: beta-chemokine-dependent and -independent effects. AIDS Res Hum Retroviruses. 13:1997;63-69
46. Appay V, Nixon DF, Donahoe SM, et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med. 192:2000;63-75
47. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med. 53:2002;557-593
48. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 357:2001;1149-1153
49. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science. 283:1999;1748-1752
50. Tang J, Costello C, Keet IP, et al. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses. 15:1999;317-324
51. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med. 54:2003;535-551
52. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 68:1994;4650-4655
53. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 68:1994;6103-6110
54. Reimann KA, Tenner-Racz K, Racz P, et al. Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol. 68:1994;2362-2370
55. Kuroda MJ, Schmitz JE, Charini WA, et al. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol. 162:1999;5127-5133
56. Allen TM, O'Connor DH, Jing P, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature. 407:2000;386-390
57. Evans DT, O'Connor DH, Jing P, et al. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med. 5:1999;1270-1276
58. McMichael A. T cell responses and viral escape. Cell. 93:1998;673-676
59. McMichael AJ, Phillips RE. Escape of human immunodeficiency virus from immune control. Annu Rev Immunol. 15:1997;271-296
60. Phillips RE, Rowland-Jones S, Nixon DF, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature. 354:1991;453-459
61. Borrow P, Lewicki H, Wei X, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med. 3:1997;205-211
62. Goulder PJ, Sewell AK, Lalloo DG, et al. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J Exp Med. 185:1997;1423-1433
63. Barouch DH, Kunstman J, Kuroda MJ, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 415:2002;335-339
64. Schmitz JE, Kuroda MJ, Sampa S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 283:1999;857-860
65. Matano T, Shibata R, Siemon C, et al. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol. 72:1998;164-169
66. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 189:1999;991-998
67. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 292:2001;69-74
68. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 415:2002;331-335
69. Feinberg MB, Moore JP. AIDS vaccine models: challenging challenge viruses. Nat Med. 8:2002;207-210
70. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 279:1998;2103-2106
71. Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med. 5:1999;518-525
72. Addo MM, Yu XG, Rathod A, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol. 77:2003;2081-2092
73. Betts MR, Ambrozak DR, Douek DC, et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol. 75:2001;11983-11991
74. Migueles SA, Laborico AC, Shupert WL, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol. 3:2002;1061-1068
75. Walker B. Limited durability of immune control following treated acute HIV infection. Keystone Symposium - HIV Vaccine Development: Progress and Prospects; 2004; Whistler, British Columbia, Canada.
76. Zhang D, Shankar P, Xu Z, et al. Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood. 101:2003;226-235
77. Altman JD, Feinberg MB. HIV escape: there and back again. Nat Med. 10:2004;229-230
78. Goulder PJ, Phillips RE, Colbert RA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med. 3:1997;212-217
79. Draenert R, Le Gall S, Pfafferott KJ, et al. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med. 199:2004;905-915
80. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature. 391:1998;397-401
81. Bobbitt KR, Addo MM, Altfeld M, et al. Rev activity determines sensitivity of HIV-1-infected primary T cells to CTL killing. Immunity. 18:2003;289-299
82. McCune JM. The dynamics of CD4+ T-cell depletion in HIV disease. Nature. 410:2001;974-979
83. Champagne P, Ogg GS, King AS, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 410:2001;106-111
84. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 4:2003;225-234
85. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 8:2002;379-385
86. van Baarle D, Kostense S, van Oers MH, et al. Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol. 23:2002;586-591
87. Garber DA, Silvestri G, Barry AP, et al. Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication. J Clin Invest. 113:2004;836-845
88. Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol. 68:1994;8056-8063
89. Zajac AJ, Blattman JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 188:1998;2205-2213
90. Harrer T, Harrer E, Kalams SA, et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses. 12:1996;585-592
91. Addo MM, Rathod A, Draenert R, et al. Immunological and genetic determinants in HIV-1 controllers and long-term non-progressors. 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, CA.
92. Rowland-Jones S, Sutton J, Ariyoshi K, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med. 1:1995;59-64
93. Rowland-Jones SL, Dong T, Fowke KR, et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest. 102:1998;1758-1765
94. Kaul R, Plummer FA, Kimani J, et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol. 164:2000;1602-1611
95. Kaul R, Dong T, Plummer FA, et al. CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest. 107:2001;1303-1310
96. Clerici M, Levin JM, Kessler HA, et al. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA. 271:1994;42-46
97. Pinto LA, Sullivan J, Berzofsky JA, et al. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest. 96:1995;867-876
98. Kaul R, Rowland-Jones SL, Kimani J, et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest. 107:2001;341-349
99. Yang OO, Boscardin WJ, Matud J, et al. Immunologic profile of highly exposed yet HIV type 1-seronegative men. AIDS Res Hum Retroviruses. 18:2002;1051-1065
100. Schmechel SC, Russell N, Hladik F, et al. Immune defence against HIV-1 infection in HIV-1-exposed seronegative persons. Immunol Lett. 79:2001;21-27
101. Mulundu G, Walker BD, Hahn BH, et al. Analysis of CTL responses in HIV-1 clade C infected and exposed uninfected individuals from Lusaka, Zambia. XIVth International AIDS Conference; 2002; Barcelona, Spain.
102. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature. 417:2002;95-98
103. Hamer DH, Hu S, Lueders KK, et al. HIV-specific CD4 T cells are a hot spot for viral evolution. Keystone Symposium - Molecular Mechanisms of HIV Pathogenesis; 2004; Whistler, British Columbia, Canada.
104. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 278:1997;1447-1450
105. Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA. 97:2000;3382-3387
106. Malhotra U, Berrey MM, Huang Y, et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis. 181:2000;121-131
107. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 407:2000;523-526
108. Oxenius A, Price DA, Gunthard HF, et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA. 99:2002;13747-13752
109. Lifson JD, Rossio JL, Piatak M Jr, et al. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol. 75:2001;10187-10199
110. Lori F, Lewis MG, Xu J, et al. Control of SIV rebound through structured treatment interruptions during early infection. Science. 290:2000;1591-1593
111. Altfeld M, Allen TM, Yu XG, et al. HIV-1 superinfection despite broad CD8(+) T-cell responses containing replication of the primary virus. Nature. 420:2002;434-439
112. Jost S, Bernard MC, Kaiser L, et al. A patient with HIV-1 superinfection. N Engl J Med. 347:2002;731-736
113. Seder RA, Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol. 4:2003;835-842
114. Wherry EJ, Blattman JN, Murali-Krishna K, Most R van der, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003; 77: 4911-4927.
115. Kaech SM, Ahmed R. Immunology. CD8 T cells remember with a little help. Science. 300:2003;263-265
116. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 300:2003;337-339
117. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 300:2003;339-342
118. Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science. 297:2002;2060-2063
119. Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 421:2003;852-856
120. Masopust D, Kaech SM, Wherry EJ, Ahmed R. The role of programming in memory T-cell development. Curr Opin Immunol. 16:2004;217-225
121. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol. 78:2004;5535-5545
122. Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol. 2:2001;415-422
123. Kaech SM, Hemby S, Kersh E, Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell. 111:2002;837-851
124. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2:2002;251-262
125. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:1995;123-126
126. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:1995;117-122
127. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 267:1995;483-489
128. Levy DN, Aldrovandi GM, Kutsch O, Shaw GM. Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci USA. 101:2004;4204-4209
129. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science. 296:2002;2354-2360
130. IAVI. Global distribution of HIV-1 subtypes and recombinants. 2003;IAVI, New York
131. Novitsky V, Smith UR, Gilbert P, et al. Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design? J Virol. 76:2002;5435-5451
132. Novitsky V, Cao H, Rybak N, et al. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol. 76:2002;10155-10168
133. Moore CB, John M, James IR, et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science. 296:2002;1439-1443
134. McMichael A, Klenerman P. HIV/AIDS. HLA leaves its footprints on HIV. Science. 296:2002;1410-1411
135. Walker BD, Korber BT. Immune control of HIV: the obstacles of HLA and viral diversity. Nat Immunol. 2:2001;473-475
136. Brander C, Walker BD. Gradual adaptation of HIV to human host populations: good or bad news? Nat Med. 9:2003;1359-1362
137. Leslie AJ, Pfafferott KJ, Chetty P, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med. 10:2004;282-289
138. Friedrich TC, Dodds EJ, Yant LJ, et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med. 10:2004;275-281
139. IAVI database of AIDS vaccines in human trials. IAVI Report. http://www.iavi.org/trialsdb (accessed June 3, 2004).
140. HIV Vaccine Trials Network. http://www.hvtn.org (accessed June 3, 2004).
141. McNeil JG, Johnston MI, Birx DL, Tramont EC. Policy rebuttal. HIV vaccine trial justified. Science. 303:2004;961
142. Cohen J. HIV/AIDS. Vaccine results lose significance under scrutiny. Science. 299:2003;1495
143. Berman PW. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retroviruses. 14:(suppl 3):1998;277-289
144. Berman PW, Huang W, Riddle L, et al. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. Virology. 265:1999;1-9
145. Cohen J. Public health. AIDS vaccine still alive as booster after second failure in Thailand. Science. 302:2003;1309-1310
146. Burton DR, Desrosiers RC, Doms RW, et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science. 303:2004;316
147. Cohen J. Disappointing data scuttle plans for large-scale AIDS vaccine trial. Science. 295:2002;1616-1617
148. Belshe RB, Gorse GJ, Mulligan MJ, et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS. 12:1998;2407-2415
149. Belshe RB, Stevens C, Gorse GJ, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis. 183:2001;1343-1352
150. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 290:2000;486-492
151. Barouch DH, Santra S, Kuroda MJ, et al. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol. 75:2001;5151-5158
152. Matano T, Kano M, Nakamura H, Takeda A, Nagai Y. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen. J Virol. 75:2001;11891-11896
153. Chen X, Scala G, Quinto I, et al. Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. Nat Med. 7:2001;1225-1231
154. Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell. 106:2001;539-549
155. Davis NL, West A, Reap E, et al. Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life. 53:2002;209-211
156. Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today. 21:2000;163-165
157. Staprans SI, Feinberg MB. The roles of non-human primates in the preclinical evaluation of candidate AIDS vaccines. Expert Rev Vaccines 2004; 3 (suppl).
158. Feinberg MB, Wright D, Piliero P, et al. The safety and immunogenicity of Merck's HIV-1 gag DNA vaccines (with or without adjuvants) in healthy adults. AIDS Vaccine 2003 Conference; 2003; New York, NY, USA.
159. Mwau M, Cebere I, Sutton J, et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol. 85:2004;911-919
160. Gilbert PB, DeGruttola VG, Hudgens MG, et al. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J Infect Dis. 188:2003;179-193
161. Datta S, Halloran ME, Longini IM Jr. Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy. Stat Med. 17:1998;185-200
162. Hudgens MG, Gilbert PB, Self SG. Endpoints in vaccine trials. Stat Methods Med Res. 13:2004;89-114
163. Hudgens MG, Hoering A, Self SG. On the analysis of viral load endpoints in HIV vaccine trials. Stat Med. 22:2003;2281-2298
164. Nabel G, Golding H, Emini E, et al. Roundtable discussion: immunogenicity criteria for advancing candidate vaccines into phase III trials. Keystone Symposium - HIV Vaccine Development: Progress and Prospects; 2004; Whistler, British Columbia, Canada.
165. Varmus H, Klausner R, Zerhouni E, et al. Public health. Grand challenges in global health. Science. 302:2003;398-399
166. Klausner RD, Fauci AS, Corey L, et al. Medicine. The need for a global HIV vaccine enterprise. Science. 300:2003;2036-2039
167. IAVI. IAVI 2003 mid-year progress report. http://www.iavi.org/pdf/ 2003_mid-year_report.pdf (accessed June 8, 2004).
168. UNAIDS. Ethical considerations in HIV preventive vaccine research: UNAIDS guidance document. 2000;UNAIDS, Geneva, Switzerland
169. Panel on clinical practices for treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services, 2004. http://aidsinfo.nih.gov/ guidelines/adult/AA_032304.pdf (accessed June 8, 2004).
170. UNAIDS. "Three ones" key principles; "coordination of national responses to HIV/AIDS"; guiding principles for national authorities and their partners. Washington, DC, USA: UNAIDS, 2004.
171. UNAIDS. Landmark agreement reached in fight against AIDS. 2004;UNAIDS, Washington, DC, USA
172. UNAIDS. Commitment to principles for concerted AIDS action at country level. 2004;UNAIDS, Washington, DC, USA
173. UNAIDS. Clearing the common ground for the "Three ones"; report of a consultation process. 2004;UNAIDS, Washington, DC, USA